Tag: genomic biomarkers market demand

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Genomic Biomarkers Market Growth From $10.24 Billion In 2026 To $19.32 Billion By 2030 At A CAGR Of 17.2%

The market for genomic biomarkers has experienced substantial expansion, projecting a rise from $8.72 billion in 2025 to $10.24 billion in 2026, reflecting a compound annual growth rate of 17.5%. This growth trajectory is underpinned by key factors observed during the earlier period, including significant progress in genomic sequencing techniques, a broader focus on biomarker research within oncology, the escalating use of tailored therapeutic strategies, enhancements in the structures for clinical validation, and the increasing accessibility of genomic data repositories.

The genomic biomarkers market is projected for swift expansion in the upcoming years. Anticipated to reach $19.33 billion by 2030, this growth trajectory reflects a compound annual growth rate (CAGR) of 17.2%. Multiple factors are expected to fuel this increase during the forecast period, including augmented funding for precision medicine initiatives, a heightened need for diagnostic tools enabling earlier disease identification, the broadening scope of drug development reliant on biomarkers, greater incorporation of artificial intelligence into genomic analysis, and escalating regulatory endorsement of individualized treatment approaches. Key developments anticipated within this timeframe involve a surge in the application of biomarker-directed precision medicine, increased utilization of genomic information in guiding clinical choices, a more prevalent use of companion diagnostics, the proliferation of multi-omics platforms for biomarker discovery, and a stronger emphasis on establishing robust clinical validation standards.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19485&type=smp

Genomic Biomarkers Market Growth Factors: Which Forces Are Supporting Market Expansion?

The elevated need for healthcare tailored to individual patients, referred to as personalized or precision medicine, is poised to be a significant driver for the expansion of the genomic biomarkers market. This tailored medical strategy leverages an individual’s genetic and genomic profile to inform healthcare choices and treatment plans. Key contributors to this rising demand include a greater focus on patient-centered healthcare, continuous advancements in genetic sequencing and analysis technologies, and the integration of Electronic Health Records for robust data management and interpretation. Genomic biomarkers are instrumental in this paradigm, empowering clinicians to customize therapies based on a patient’s specific genetic composition, thereby enhancing treatment efficacy and mitigating adverse reactions. A notable illustration of this trend is the U.S. Food and Drug Administration’s approval of 16 new personalized treatments for rare disease patients in 2023, a substantial increase from the six approvals in 2022, as highlighted by the Personalized Medicine Coalition in February 2024. Consequently, the growing imperative for personalized medicine directly fuels the growth trajectory of the genomic biomarkers market.

Genomic Biomarkers Market Segments: Where Are The Largest Growth Opportunities?

The genomic biomarkers market covered in this report is segmented –

1) By Type: Predictive Biomarkers, Prognostic Biomarkers

2) By Disease Indication: Oncology, Cardiovascular Diseases, Neurological Diseases, Renal Disorders, Other Disease Indications

3) By Validation: Analytical Validation, Clinical Validation, Clinical Utility

4) By End-User: Hospitals, Diagnostic Centers, Other End-Users

Subsegments:

1) By Predictive Biomarkers: Drug Response Biomarkers, Companion Diagnostics Biomarkers, Pharmacodynamic Biomarkers, Predictive Genetic Markers for Disease Susceptibility

2) By Prognostic Biomarkers: Cancer Prognostic Biomarkers, Cardiovascular Disease Prognostic Biomarkers, Neurodegenerative Disease Prognostic Biomarkers, Infectious Disease Prognostic Biomarkers

Genomic Biomarkers Market Industry Trends: What Changes Are Reshaping Demand?

Key players within the genomic biomarkers sector are concentrating their efforts on the creation of novel offerings, such as reagents for lung cancer diagnostics, aimed at refining the identification of particular genetic anomalies, boosting the precision of diagnoses, and enabling tailored therapeutic strategies through the application of cutting-edge genomic techniques. These specialized lung reagents, which are chemical or biological agents crucial for diagnostic assays, investigative studies, or therapeutic interventions concerning the lungs, play a vital role in advancing precision medicine by informing treatment decisions based on an individual’s unique cancer genetic makeup. As an illustration, in December 2023, Biofidelity, a United Kingdom enterprise dedicated to the advancement of sophisticated genomic testing and diagnostic accuracy, introduced its ASPYRE-Lung reagents. The purpose of the ASPYRE-Lung reagents is to pinpoint significant genetic mutations and changes within lung cancer, which are instrumental in directing the selection of targeted treatments and personalized care plans.

Genomic Biomarkers Market Major Participants And Competitive Dynamics

Major companies operating in the genomic biomarkers market are Thermo Fisher Scientific Inc., Roche Diagnostics International Ltd., Illumina Inc., PerkinElmer Inc., Almac Group, Azenta Inc., Novogene Corporation, Oxford Nanopore Technologies Ltd., Celerion, Quanterix Corporation, Bio-Rad Laboratories Inc., NantHealth Inc., Centogene N.V., Sophia Genetics SA, Envisagenics, Deep Genomics, Creative Diagnostics, Macrogen Inc., Guardant Health Inc., Sema4

Access The Complete Genomic Biomarkers Market Report:

https://www.thebusinessresearchcompany.com/report/genomic-biomarkers-global-market-report

Genomic Biomarkers Market Geographic Landscape: Which Region Dominates Industry Growth?

North Americawas the largest region in the genomic biomarkers market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the genomic biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Genomic Biomarkers Market Growth From $10.24 Billion In 2026 To $19.32 Billion By 2030 At A CAGR Of 17.2%

The market for genomic biomarkers has experienced substantial expansion, projecting a rise from $8.72 billion in 2025 to $10.24 billion in 2026, reflecting a compound annual growth rate of 17.5%. This growth trajectory is underpinned by key factors observed during the earlier period, including significant progress in genomic sequencing techniques, a broader focus on biomarker research within oncology, the escalating use of tailored therapeutic strategies, enhancements in the structures for clinical validation, and the increasing accessibility of genomic data repositories.

The genomic biomarkers market is projected for swift expansion in the upcoming years. Anticipated to reach $19.33 billion by 2030, this growth trajectory reflects a compound annual growth rate (CAGR) of 17.2%. Multiple factors are expected to fuel this increase during the forecast period, including augmented funding for precision medicine initiatives, a heightened need for diagnostic tools enabling earlier disease identification, the broadening scope of drug development reliant on biomarkers, greater incorporation of artificial intelligence into genomic analysis, and escalating regulatory endorsement of individualized treatment approaches. Key developments anticipated within this timeframe involve a surge in the application of biomarker-directed precision medicine, increased utilization of genomic information in guiding clinical choices, a more prevalent use of companion diagnostics, the proliferation of multi-omics platforms for biomarker discovery, and a stronger emphasis on establishing robust clinical validation standards.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19485&type=smp

Genomic Biomarkers Market Growth Factors: Which Forces Are Supporting Market Expansion?

The elevated need for healthcare tailored to individual patients, referred to as personalized or precision medicine, is poised to be a significant driver for the expansion of the genomic biomarkers market. This tailored medical strategy leverages an individual’s genetic and genomic profile to inform healthcare choices and treatment plans. Key contributors to this rising demand include a greater focus on patient-centered healthcare, continuous advancements in genetic sequencing and analysis technologies, and the integration of Electronic Health Records for robust data management and interpretation. Genomic biomarkers are instrumental in this paradigm, empowering clinicians to customize therapies based on a patient’s specific genetic composition, thereby enhancing treatment efficacy and mitigating adverse reactions. A notable illustration of this trend is the U.S. Food and Drug Administration’s approval of 16 new personalized treatments for rare disease patients in 2023, a substantial increase from the six approvals in 2022, as highlighted by the Personalized Medicine Coalition in February 2024. Consequently, the growing imperative for personalized medicine directly fuels the growth trajectory of the genomic biomarkers market.

Genomic Biomarkers Market Segments: Where Are The Largest Growth Opportunities?

The genomic biomarkers market covered in this report is segmented –

1) By Type: Predictive Biomarkers, Prognostic Biomarkers

2) By Disease Indication: Oncology, Cardiovascular Diseases, Neurological Diseases, Renal Disorders, Other Disease Indications

3) By Validation: Analytical Validation, Clinical Validation, Clinical Utility

4) By End-User: Hospitals, Diagnostic Centers, Other End-Users

Subsegments:

1) By Predictive Biomarkers: Drug Response Biomarkers, Companion Diagnostics Biomarkers, Pharmacodynamic Biomarkers, Predictive Genetic Markers for Disease Susceptibility

2) By Prognostic Biomarkers: Cancer Prognostic Biomarkers, Cardiovascular Disease Prognostic Biomarkers, Neurodegenerative Disease Prognostic Biomarkers, Infectious Disease Prognostic Biomarkers

Genomic Biomarkers Market Industry Trends: What Changes Are Reshaping Demand?

Key players within the genomic biomarkers sector are concentrating their efforts on the creation of novel offerings, such as reagents for lung cancer diagnostics, aimed at refining the identification of particular genetic anomalies, boosting the precision of diagnoses, and enabling tailored therapeutic strategies through the application of cutting-edge genomic techniques. These specialized lung reagents, which are chemical or biological agents crucial for diagnostic assays, investigative studies, or therapeutic interventions concerning the lungs, play a vital role in advancing precision medicine by informing treatment decisions based on an individual’s unique cancer genetic makeup. As an illustration, in December 2023, Biofidelity, a United Kingdom enterprise dedicated to the advancement of sophisticated genomic testing and diagnostic accuracy, introduced its ASPYRE-Lung reagents. The purpose of the ASPYRE-Lung reagents is to pinpoint significant genetic mutations and changes within lung cancer, which are instrumental in directing the selection of targeted treatments and personalized care plans.

Genomic Biomarkers Market Major Participants And Competitive Dynamics

Major companies operating in the genomic biomarkers market are Thermo Fisher Scientific Inc., Roche Diagnostics International Ltd., Illumina Inc., PerkinElmer Inc., Almac Group, Azenta Inc., Novogene Corporation, Oxford Nanopore Technologies Ltd., Celerion, Quanterix Corporation, Bio-Rad Laboratories Inc., NantHealth Inc., Centogene N.V., Sophia Genetics SA, Envisagenics, Deep Genomics, Creative Diagnostics, Macrogen Inc., Guardant Health Inc., Sema4

Access The Complete Genomic Biomarkers Market Report:

https://www.thebusinessresearchcompany.com/report/genomic-biomarkers-global-market-report

Genomic Biomarkers Market Geographic Landscape: Which Region Dominates Industry Growth?

North Americawas the largest region in the genomic biomarkers market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the genomic biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Genomic Biomarkers Market Growth From $10.24 Billion In 2026 To $19.32 Billion By 2030 At A CAGR Of 17.2%

The market for genomic biomarkers has experienced substantial expansion, projecting a rise from $8.72 billion in 2025 to $10.24 billion in 2026, reflecting a compound annual growth rate of 17.5%. This growth trajectory is underpinned by key factors observed during the earlier period, including significant progress in genomic sequencing techniques, a broader focus on biomarker research within oncology, the escalating use of tailored therapeutic strategies, enhancements in the structures for clinical validation, and the increasing accessibility of genomic data repositories.

The genomic biomarkers market is projected for swift expansion in the upcoming years. Anticipated to reach $19.33 billion by 2030, this growth trajectory reflects a compound annual growth rate (CAGR) of 17.2%. Multiple factors are expected to fuel this increase during the forecast period, including augmented funding for precision medicine initiatives, a heightened need for diagnostic tools enabling earlier disease identification, the broadening scope of drug development reliant on biomarkers, greater incorporation of artificial intelligence into genomic analysis, and escalating regulatory endorsement of individualized treatment approaches. Key developments anticipated within this timeframe involve a surge in the application of biomarker-directed precision medicine, increased utilization of genomic information in guiding clinical choices, a more prevalent use of companion diagnostics, the proliferation of multi-omics platforms for biomarker discovery, and a stronger emphasis on establishing robust clinical validation standards.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19485&type=smp

Genomic Biomarkers Market Growth Factors: Which Forces Are Supporting Market Expansion?

The elevated need for healthcare tailored to individual patients, referred to as personalized or precision medicine, is poised to be a significant driver for the expansion of the genomic biomarkers market. This tailored medical strategy leverages an individual’s genetic and genomic profile to inform healthcare choices and treatment plans. Key contributors to this rising demand include a greater focus on patient-centered healthcare, continuous advancements in genetic sequencing and analysis technologies, and the integration of Electronic Health Records for robust data management and interpretation. Genomic biomarkers are instrumental in this paradigm, empowering clinicians to customize therapies based on a patient’s specific genetic composition, thereby enhancing treatment efficacy and mitigating adverse reactions. A notable illustration of this trend is the U.S. Food and Drug Administration’s approval of 16 new personalized treatments for rare disease patients in 2023, a substantial increase from the six approvals in 2022, as highlighted by the Personalized Medicine Coalition in February 2024. Consequently, the growing imperative for personalized medicine directly fuels the growth trajectory of the genomic biomarkers market.

Genomic Biomarkers Market Segments: Where Are The Largest Growth Opportunities?

The genomic biomarkers market covered in this report is segmented –

1) By Type: Predictive Biomarkers, Prognostic Biomarkers

2) By Disease Indication: Oncology, Cardiovascular Diseases, Neurological Diseases, Renal Disorders, Other Disease Indications

3) By Validation: Analytical Validation, Clinical Validation, Clinical Utility

4) By End-User: Hospitals, Diagnostic Centers, Other End-Users

Subsegments:

1) By Predictive Biomarkers: Drug Response Biomarkers, Companion Diagnostics Biomarkers, Pharmacodynamic Biomarkers, Predictive Genetic Markers for Disease Susceptibility

2) By Prognostic Biomarkers: Cancer Prognostic Biomarkers, Cardiovascular Disease Prognostic Biomarkers, Neurodegenerative Disease Prognostic Biomarkers, Infectious Disease Prognostic Biomarkers

Genomic Biomarkers Market Industry Trends: What Changes Are Reshaping Demand?

Key players within the genomic biomarkers sector are concentrating their efforts on the creation of novel offerings, such as reagents for lung cancer diagnostics, aimed at refining the identification of particular genetic anomalies, boosting the precision of diagnoses, and enabling tailored therapeutic strategies through the application of cutting-edge genomic techniques. These specialized lung reagents, which are chemical or biological agents crucial for diagnostic assays, investigative studies, or therapeutic interventions concerning the lungs, play a vital role in advancing precision medicine by informing treatment decisions based on an individual’s unique cancer genetic makeup. As an illustration, in December 2023, Biofidelity, a United Kingdom enterprise dedicated to the advancement of sophisticated genomic testing and diagnostic accuracy, introduced its ASPYRE-Lung reagents. The purpose of the ASPYRE-Lung reagents is to pinpoint significant genetic mutations and changes within lung cancer, which are instrumental in directing the selection of targeted treatments and personalized care plans.

Genomic Biomarkers Market Major Participants And Competitive Dynamics

Major companies operating in the genomic biomarkers market are Thermo Fisher Scientific Inc., Roche Diagnostics International Ltd., Illumina Inc., PerkinElmer Inc., Almac Group, Azenta Inc., Novogene Corporation, Oxford Nanopore Technologies Ltd., Celerion, Quanterix Corporation, Bio-Rad Laboratories Inc., NantHealth Inc., Centogene N.V., Sophia Genetics SA, Envisagenics, Deep Genomics, Creative Diagnostics, Macrogen Inc., Guardant Health Inc., Sema4

Access The Complete Genomic Biomarkers Market Report:

https://www.thebusinessresearchcompany.com/report/genomic-biomarkers-global-market-report

Genomic Biomarkers Market Geographic Landscape: Which Region Dominates Industry Growth?

North Americawas the largest region in the genomic biomarkers market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the genomic biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Genomic Biomarkers Market Progress Between 2026 And 2030?

The genomic biomarkers market has seen significant growth in its size over recent years. It is anticipated to increase from $8.72 billion in 2025 to $10.24 billion in 2026, reflecting a compound annual growth rate (CAGR) of 17.5%. This historical expansion can be primarily attributed to advancements in genomic sequencing technologies, the expansion of oncology-focused biomarker research, the increasing adoption of personalized treatment approaches, improvements in clinical validation frameworks, and the rising availability of genomic databases.

The genomic biomarkers market is set for substantial growth over the coming years, with its valuation expected to reach $19.33 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 17.2%. This anticipated expansion during the forecast period is propelled by increasing investments in precision medicine programs, a rising demand for early disease detection tools, the expansion of biomarker-driven drug development, the growing integration of AI in biomarker analysis, and increasing regulatory support for personalized therapies. Significant trends shaping this period include the increasing adoption of biomarker-guided precision medicine, the rising integration of genomic data in clinical decision-making, a growing use of companion diagnostics, the expansion of multi-omics biomarker platforms, and an enhanced focus on clinical validation standards.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/genomic-biomarkers-global-market-report

What Key Factors Are Affecting The Genomic Biomarkers Market Demand?

The rising need for personalized medicine is projected to fuel the expansion of the genomic biomarkers market in the future. Personalized medicine, interchangeably called precision medicine, represents a healthcare strategy designed to customize medical choices and therapies according to each patient’s unique attributes, largely relying on their genetic and genomic data. This escalating requirement for personalized medicine stems from multiple elements, including the heightened focus on patient-focused care, advancements in genetic sequencing and analysis, a patient-centric methodology, and the utilization of EHRs for patient data storage and examination. Genomic biomarkers are instrumental in personalized medicine, allowing healthcare professionals to adapt medical therapies to an individual’s distinct genetic profile. This methodology, also termed precision medicine, endeavors to maximize treatment efficacy and reduce adverse reactions by taking into account the genetic variations among individuals. For example, in February 2024, the Personalized Medicine Coalition, a US-based professional membership organization, reported that in 2023, the FDA sanctioned 16 novel personalized therapies for rare disease patients, an increase from six in 2022. Consequently, the escalating need for personalized medicine propels the expansion of the genomic biomarkers market.

How Are Different Segments Classified In The Genomic Biomarkers Market Segment Analysis?

The genomic biomarkers market covered in this report is segmented –

1) By Type: Predictive Biomarkers, Prognostic Biomarkers

2) By Disease Indication: Oncology, Cardiovascular Diseases, Neurological Diseases, Renal Disorders, Other Disease Indications

3) By Validation: Analytical Validation, Clinical Validation, Clinical Utility

4) By End-User: Hospitals, Diagnostic Centers, Other End-Users

Subsegments:

1) By Predictive Biomarkers: Drug Response Biomarkers, Companion Diagnostics Biomarkers, Pharmacodynamic Biomarkers, Predictive Genetic Markers for Disease Susceptibility

2) By Prognostic Biomarkers: Cancer Prognostic Biomarkers, Cardiovascular Disease Prognostic Biomarkers, Neurodegenerative Disease Prognostic Biomarkers, Infectious Disease Prognostic Biomarkers

What Trends Are Influencing Changes In The Genomic Biomarkers Market?

Leading companies in the genomic biomarkers market are concentrating on creating innovative products, such as lung reagents, to improve the identification of specific genetic mutations in lung cancer, enhance diagnostic precision, and enable personalized treatment strategies by utilizing advanced genomic technologies. Lung reagents are specialized chemical or biological substances used in diagnostic tests, research, or medical procedures pertaining to the lungs, aiding precision medicine by guiding treatment choices based on the cancer’s unique genetic profile. For instance, in December 2023, Biofidelity, a UK-based company specializing in advanced genomic assays and precision diagnostics, introduced ASPYRE-Lung reagents. These ASPYRE-Lung reagents are developed to pinpoint key genetic mutations and alterations in lung cancer, which are essential for directing targeted therapies and individualized treatment plans.

Who Are The Companies Driving Activity In The Genomic Biomarkers Market?

Major companies operating in the genomic biomarkers market are Thermo Fisher Scientific Inc., Roche Diagnostics International Ltd., Illumina Inc., PerkinElmer Inc., Almac Group, Azenta Inc., Novogene Corporation, Oxford Nanopore Technologies Ltd., Celerion, Quanterix Corporation, Bio-Rad Laboratories Inc., NantHealth Inc., Centogene N.V., Sophia Genetics SA, Envisagenics, Deep Genomics, Creative Diagnostics, Macrogen Inc., Guardant Health Inc., Sema4

Get The Full Genomic Biomarkers Market Report:

https://www.thebusinessresearchcompany.com/report/genomic-biomarkers-global-market-report

Where Is The Genomic Biomarkers Market Most Concentrated Geographically?

North America was the largest region in the genomic biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomic biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Genomic Biomarkers Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/genomic-biomarkers-global-market-report

Browse Through More Reports Similar to the Global Genomic Biomarkers Market 2026, By The Business Research Company

Digital Genome Market Report 2026

https://www.thebusinessresearchcompany.com/report/digital-genome-global-market-report

Single Cell Genome Sequencing Market Report 2026

https://www.thebusinessresearchcompany.com/report/single-cell-genome-sequencing-global-market-report

Whole Genome And Exome Sequencing Market Report 2026

https://www.thebusinessresearchcompany.com/report/whole-genome-and-exome-sequencing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Forecasted Market Value Of The Genomic Biomarkers Market Across 2026–2030?

The genomic biomarkers market has seen rapid expansion in recent years. Its valuation is anticipated to rise from $8.72 billion in 2025 to $10.24 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 17.5%. The expansion observed historically is largely due to progress in genomic sequencing technologies, a surge in oncology-focused biomarker research, the wider acceptance of personalized treatment methods, refinements in clinical validation structures, and the increasing availability of genomic databases.

The genomic biomarkers market is poised for significant expansion in the coming years, with its valuation projected to reach $19.33 billion by 2030, driven by a robust compound annual growth rate (CAGR) of 17.2%. This anticipated growth stems from several factors, including heightened investments in precision medicine initiatives, a greater need for early disease identification tools, the broadening scope of biomarker-guided drug development, the increasing incorporation of AI in biomarker analysis, and strengthened regulatory backing for individualized treatments. Key developments expected during this period involve a greater embrace of biomarker-informed precision medicine, the escalating integration of genomic data into clinical decision-making processes, the expanded application of companion diagnostics, the proliferation of multi-omics biomarker platforms, and a sharper emphasis on standards for clinical validation.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19485&type=smp

What Primary Drivers Are Shaping The Development Of The Genomic Biomarkers Market?

The genomic biomarkers market is anticipated to expand due to the rising demand for personalized medicine. Personalized medicine, also known as precision medicine, is a medical strategy that customizes healthcare choices and therapies for each patient’s specific traits, mainly using their genetic and genomic data. This growing need for personalized medicine stems from factors like a greater focus on patient-centered care, advancements in genetic sequencing and analysis, a patient-centric methodology, and the utilization of EHRs for data storage and analysis. Genomic biomarkers are vital in personalized medicine, allowing healthcare providers to adapt medical treatments to an individual’s distinct genetic profile. This methodology, also referred to as precision medicine, seeks to enhance treatment efficacy and reduce adverse effects by accounting for genetic variations among individuals. For example, the Personalized Medicine Coalition, a US-based professional membership organization, reported in February 2024 that the FDA approved 16 new personalized treatments for rare disease patients in 2023, an increase from six in 2022. Consequently, the expanding demand for personalized medicine propels the growth of the genomic biomarkers market.

What Segmentation Levels Are Considered In The Genomic Biomarkers Market?

The genomic biomarkers market covered in this report is segmented –

1) By Type: Predictive Biomarkers, Prognostic Biomarkers

2) By Disease Indication: Oncology, Cardiovascular Diseases, Neurological Diseases, Renal Disorders, Other Disease Indications

3) By Validation: Analytical Validation, Clinical Validation, Clinical Utility

4) By End-User: Hospitals, Diagnostic Centers, Other End-Users

Subsegments:

1) By Predictive Biomarkers: Drug Response Biomarkers, Companion Diagnostics Biomarkers, Pharmacodynamic Biomarkers, Predictive Genetic Markers for Disease Susceptibility

2) By Prognostic Biomarkers: Cancer Prognostic Biomarkers, Cardiovascular Disease Prognostic Biomarkers, Neurodegenerative Disease Prognostic Biomarkers, Infectious Disease Prognostic Biomarkers

Which Trends Are Influencing The Genomic Biomarkers Market?

Major companies operating in the genomic biomarkers market are focused on developing innovative products, such as lung reagents, to enhance the detection of specific genetic mutations in lung cancer, improve diagnostic accuracy, and facilitate personalized treatment approaches by leveraging advanced genomic technologies. Lung reagents refer to specialized chemical or biological substances used in diagnostic tests, research, or medical procedures related to the lungs, helping in precision medicine by guiding treatment choices based on the specific genetic profile of the cancer. For instance, in December 2023, Biofidelity, a UK-based company specializing in developing advanced genomic assays and precision diagnostics, launched ASPYRE-Lung reagents. The ASPYRE-Lung reagents are designed to identify key genetic mutations and alterations in lung cancer, which are critical for guiding targeted therapies and personalized treatment strategies.

Which Leading Firms Are Contributing To The Growth Of The Genomic Biomarkers Market?

Major companies operating in the genomic biomarkers market are Thermo Fisher Scientific Inc., Roche Diagnostics International Ltd., Illumina Inc., PerkinElmer Inc., Almac Group, Azenta Inc., Novogene Corporation, Oxford Nanopore Technologies Ltd., Celerion, Quanterix Corporation, Bio-Rad Laboratories Inc., NantHealth Inc., Centogene N.V., Sophia Genetics SA, Envisagenics, Deep Genomics, Creative Diagnostics, Macrogen Inc., Guardant Health Inc., Sema4

Read the full genomic biomarkers market report here:

https://www.thebusinessresearchcompany.com/report/genomic-biomarkers-global-market-report

How Does The Genomic Biomarkers Market Perform Across Major Global Regions?

North America was the largest region in the genomic biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomic biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Genomic Biomarkers Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19485&type=smp

Browse Through More Reports Similar to the Global Genomic Biomarkers Market 2026, By The Business Research Company

Genomics Global Market Report

https://www.thebusinessresearchcompany.com/report/genomics-global-market-report

Genomics Personalized Health Global Market Report

https://www.thebusinessresearchcompany.com/report/genomics-personalized-health-global-market-report

Consumer Genomics Global Market Report

https://www.thebusinessresearchcompany.com/report/consumer-genomics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model